Agile Therapeutics, Inc. (NASDAQ:AGRX)‘s stock had its “buy” rating reissued by investment analysts at Cantor Fitzgerald in a research note issued on Monday. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 58.73% from the company’s current price.
A number of other analysts also recently commented on AGRX. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research report on Sunday, July 30th. Janney Montgomery Scott restated a “buy” rating and set a $13.00 price target (down from $15.00) on shares of Agile Therapeutics in a research report on Thursday, August 24th. ValuEngine downgraded shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Royal Bank Of Canada boosted their price target on shares of Agile Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, September 14th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Agile Therapeutics in a research report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $10.20.
Shares of Agile Therapeutics (NASDAQ AGRX) opened at $5.04 on Monday. Agile Therapeutics has a 52-week low of $1.82 and a 52-week high of $7.09. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. equities research analysts forecast that Agile Therapeutics will post -0.99 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/22/agile-therapeutics-inc-agrx-stock-rating-reaffirmed-by-cantor-fitzgerald.html.
In other Agile Therapeutics news, Chairman Alfred Altomari bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were acquired at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the acquisition, the chairman now directly owns 161,587 shares of the company’s stock, valued at $539,700.58. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 3.50% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after purchasing an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Agile Therapeutics in the 2nd quarter worth approximately $122,000. OxFORD Asset Management LLP bought a new stake in shares of Agile Therapeutics in the 3rd quarter worth approximately $161,000. Susquehanna International Group LLP bought a new stake in shares of Agile Therapeutics in the 2nd quarter worth approximately $205,000. Finally, LMR Partners LLP bought a new stake in shares of Agile Therapeutics in the 2nd quarter worth approximately $211,000. Institutional investors and hedge funds own 68.45% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.